Novartis' new eye drug undercuts Bayer's rival with fewer in...

The FDA has approved Novartis’s new eye drug brolucizumab for wet age-related macular degeneration, which will match Bayer’s rival Eylea on price per dose but reduce costs with a less frequ

MHRA says Avastin can be used for AMD despite Bayer, Novarti...

Novartis challenges court ruling allowing use of Avastin in ...

Novartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD)

Ionis and Roche to develop RNAi AMD drug in $760m deal

Ionis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug to treat advanced age-related macular degeneration (AMD), a leading cause of blindness.

Novartis next generation eye drug outperforms Eylea

Brolucizumab could offer quarterly dosing schedule.

Novartis/Ophthotech eye combo fails in phase 3

Lucentis and pegpleranib combination misses goal in wet AMD.